Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) CEO Saurabh Saha sold 55,000 shares of the firm’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $16.53, for a total value of $909,150.00. Following the transaction, the chief executive officer now owns 721,924 shares of the company’s stock, valued at $11,933,403.72. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Saurabh Saha also recently made the following trade(s):
- On Tuesday, September 10th, Saurabh Saha sold 175,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.52, for a total value of $2,891,000.00.
- On Thursday, August 22nd, Saurabh Saha sold 506 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $12.23, for a total value of $6,188.38.
- On Tuesday, August 20th, Saurabh Saha sold 4,169 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $12.32, for a total value of $51,362.08.
Centessa Pharmaceuticals Price Performance
Shares of NASDAQ CNTA opened at $16.58 on Monday. The firm has a market capitalization of $1.67 billion, a PE ratio of -11.68 and a beta of 1.44. Centessa Pharmaceuticals plc has a fifty-two week low of $5.15 and a fifty-two week high of $17.59. The stock’s 50-day simple moving average is $12.41 and its 200-day simple moving average is $10.67. The company has a debt-to-equity ratio of 0.27, a quick ratio of 13.29 and a current ratio of 13.29.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on CNTA shares. Guggenheim lifted their price objective on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Oppenheimer reiterated an “outperform” rating and issued a $14.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. B. Riley started coverage on Centessa Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $33.00 price objective for the company. Jefferies Financial Group lifted their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Finally, Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $11.00 to $26.00 in a research note on Thursday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $25.17.
View Our Latest Research Report on CNTA
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the company. Quarry LP increased its position in Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after buying an additional 3,108 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Centessa Pharmaceuticals by 69.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company’s stock worth $122,000 after buying an additional 4,423 shares during the period. EntryPoint Capital LLC acquired a new position in Centessa Pharmaceuticals during the first quarter worth approximately $109,000. Sandia Investment Management LP acquired a new position in Centessa Pharmaceuticals during the second quarter worth approximately $90,000. Finally, Fred Alger Management LLC acquired a new position in Centessa Pharmaceuticals during the second quarter worth approximately $99,000. Institutional investors and hedge funds own 82.01% of the company’s stock.
Centessa Pharmaceuticals Company Profile
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.
See Also
- Five stocks we like better than Centessa Pharmaceuticals
- Insider Trades May Not Tell You What You Think
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Following Congress Stock Trades
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.